A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy

The Timed “Up & Go”: A Test of Basic Functional Mobility for Frail Elderly Persons

Podsiadlo, D., & Richardson, S. (1991) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1991.tb01616.x · Cited by 14,418 · see citing works

Untitled work

(1976) · Medical Entomology and Zoology · Cited by 8,899 · see citing works

EQ-SD: a measure of health status from the EuroQol Group

Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613 · see citing works

The FAB: A frontal assessment battery at bedside

Dubois, B., Slachevsky, A., Litvan, I., & Pillon, B. (2000) · Neurology · doi:10.1212/wnl.55.11.1621 · Cited by 3,913 · see citing works

Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop*

Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538 · see citing works

Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale

Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,165 · see citing works

Recent Developments in Parkinson's Disease

Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,926 · see citing works

A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT

Wahlund, L., Barkhof, F., Fazekas, F., Bronge, L. H., Augustin, M., Sjögren, M. J. C., Wallin, A., Adèr, H. J., Leys, D., Pantoni, L., et al. (2001) · Stroke · doi:10.1161/01.str.32.6.1318 · Cited by 1,797 · see citing works

The glamour and gloom of glycogen synthase kinase-3

Jope, R. S., & Johnson, G. V. W. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.12.004 · Cited by 1,522 · see citing works

Reliability, validity, and clinical correlates of apathy in Parkinson's disease

STARKSTEIN, S. E., Mayberg, H. S., Preziosi, T. J., Andrezejewski, P., Leiguarda, R. C., & Robinson, R. G. (1992) · Journal of Neuropsychiatry · doi:10.1176/jnp.4.2.134 · Cited by 1,187 · see citing works

GSK-3β Regulates Phosphorylation of CRMP-2 and Neuronal Polarity

Yoshimura, T., Kawano, Y., Arimura, N., Kawabata, S., Kikuchi, A., & Kaibuchi, K. (2005) · Cell · doi:10.1016/j.cell.2004.11.012 · Cited by 877 · see citing works

Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges

Williams, D. R., & Lees, A. J. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70042-0 · Cited by 650 · see citing works

A clinical rating scale for progressive supranuclear palsy

Golbe, L. I., & Ohman‐Strickland, P. (2007) · Brain · doi:10.1093/brain/awm032 · Cited by 614 · see citing works

Pharmacological inhibitors of glycogen synthase kinase 3

Meijer, L., Flajolet, M., & Greengard, P. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.07.006 · Cited by 586 · see citing works

First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease

Martı́nez, A., Alonso, M., Castro, A., Pérez, C., & Moreno, F. J. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011020u · Cited by 457 · see citing works

CREB DNA binding activity is inhibited by glycogen synthase kinase‐3β and facilitated by lithium

Grimes, C. A., & Jope, R. S. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00495.x · Cited by 437 · see citing works

Glycogen synthase kinase 3: a drug target for CNS therapies

Bhat, R. V., Haeberlein, S. L. B., & Ávila, J. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02422.x · Cited by 408 · see citing works

A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo

Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., Agulló, J. M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.025 · Cited by 368 · see citing works

Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study

Bensimon, G., Ludolph, A., Agid, Y., Vidailhet, M., Payan, C., & Leigh, P. N. (2008) · Brain · doi:10.1093/brain/awn291 · Cited by 345 · see citing works

Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study

del Ser, T., Steinwachs, K. C., Gertz, H. J., Andrés, M. V., Gómez-Carrillo, B., Medina, M., Vericat, J. A., Redondo, P., Fleet, D., & León, T. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120805 · Cited by 329 · see citing works

Aβ1-42 inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β

Jo, J., Whitcomb, D. J., Olsen, K. M., Kerrigan, T. L., Lo, S.-C., Bru-Mercier, G., Dickinson, B., Scullion, S., Sheng, M., Collingridge, G., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2785 · Cited by 305 · see citing works

Current Advances on Different Kinases Involved in Tau Phosphorylation, and Implications in Alzheimers Disease and Tauopathies

Ferrer, I., Gómez‐Isla, T., Puig, B., Freixes, M., Ribé, E. M., Dalfó, E., & Ávila, J. (2005) · Current Alzheimer Research · doi:10.2174/1567205052772713 · Cited by 302 · see citing works

Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib

Domı́nguez, J. M., Fuertes, A., Orozco, L., del Monte-Millán, M., Delgado, E., & Medina, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.306472 · Cited by 249 · see citing works

Third symposium on Parkinson's disease

Walton, J. (1970) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(70)90143-7 · Cited by 236 · see citing works

Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease

DaRocha-Souto, B., Coma, M., Pérez-Nievas, B. G., Scotton, T. C., Siao, M., Sánchez-Ferrer, P., Hashimoto, T., Fan, Z., Hudry, E., Barroeta, I., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.09.002 · Cited by 180 · see citing works

Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy

Litvan, I., Phipps, M., Pharr, V., Hallett, M., Grafman, J. H., & Salazar, A. (2001) · Neurology · doi:10.1212/wnl.57.3.467 · Cited by 163 · see citing works

Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial

Höglinger, G. U., Huppertz, H., Wagenpfeil, S., Andrés, M. V., Belloch, V., León, T., del Ser, T., & for the TAUROS MRI Investigators (2014) · Movement Disorders · doi:10.1002/mds.25815 · Cited by 161 · see citing works

Short‐term effects of coenzyme Q10 in progressive supranuclear palsy: A randomized, placebo‐controlled trial

Stamelou, M., Reuß, A., Pilatus, U., Magerkurth, J., Niklowitz, P., Eggert, K. M., Krisp, A., Menke, T., Schade‐Brittinger, C., Oertel, W. H., et al. (2008) · Movement Disorders · doi:10.1002/mds.22023 · Cited by 150 · see citing works

Progressive supranuclear palsy: where are we now?

Burn, D. J., & Lees, A. J. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00161-8 · Cited by 137 · see citing works

NP031112, a Thiadiazolidinone Compound, Prevents Inflammation and Neurodegeneration under Excitotoxic Conditions: Potential Therapeutic Role in Brain Disorders

Luna‐Medina, R., Cortés‐Canteli, M., Sánchez-Galiano, S., Morales-Garcia, J. A., Martı́nez, A., Santos, Á., & Pérez‐Castillo, A. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1004-07.2007 · Cited by 114 · see citing works

Rational therapeutic approaches to progressive supranuclear palsy

Stamelou, M., de Silva, R., Arias-Carrion, O., Boura, E., Hollerhage, M., Oertel, W. H., Muller, U., & Hoglinger, G. U. (2010) · Brain · doi:10.1093/brain/awq115 · Cited by 91 · see citing works

Donepezil in the treatment of progressive supranuclear palsy

Fabbrini, G., Barbanti, P., Bonifati, V., Colosimo, C., Gasparini, M., Vanacore, N., & Meco, G. (2001) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2001.103002123.x · Cited by 84 · see citing works

Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic.

Medina, M., & Castro, A. C. G. (2008) · PubMed · Cited by 83 · see citing works

Idazoxan treatment in progressive supranuclear palsy

Ghika, J. A., Tennis, M. K., Hoffman, E., Schoenfeld, D., & Growdon, J. H. (1991) · Neurology · doi:10.1212/wnl.41.7.986 · Cited by 74 · see citing works

Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes

Beurel, E., & Jope, R. S. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.05.044 · Cited by 59 · see citing works

Balance and Eye Movement Training to Improve Gait in People With Progressive Supranuclear Palsy: Quasi-Randomized Clinical Trial

Zampieri, C., & Fabio, R. A. (2008) · Physical Therapy · doi:10.2522/ptj.20070302 · Cited by 59 · see citing works

Phosphorylation of Neuronal Survival Factor MEF2D by Glycogen Synthase Kinase 3β in Neuronal Apoptosis

Wang, X., She, H., & Mao, Z. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.067785 · Cited by 57 · see citing works

Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis

Liepelt, I., Gaenslen, A., Godau, J., Santo, A. D., Schweitzer, K., Gasser, T., & Berg, D. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.1231 · Cited by 47 · see citing works

Editorial - Progress of Current Alzheimer Research

Lahiri, D. K. (2005) · Current Alzheimer Research · doi:10.2174/1567205052772696 · Cited by 4 · see citing works

Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases

Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768 · see citing works

Tau-targeting therapies for Alzheimer disease

Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · see citing works

A Phase II Trial of Tideglusib in Alzheimer's Disease

Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536 · see citing works

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches

Boxer, A. L., Yu, J.-T., Golbe, L. I., Litvan, I., Lang, A. E., & Höglinger, G. U. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30157-6 · Cited by 485 · see citing works

Targeting hepatic glucose metabolism in the treatment of type 2 diabetes

Rines, A. K., Sharabi, K., Tavares, C. D. J., & Puigserver, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.151 · Cited by 380 · see citing works

Diabetes mellitus and Alzheimer's disease: GSK-3β as a potential link

Zhang, Y., Huang, N.-Q., Yan, F., Jin, H., Zhou, S.-Y., Shi, J.-S., & Jin, F. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.11.015 · Cited by 301 · see citing works

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

Boxer, A. L., Lang, A. E., Grossman, M., Knopman, D. S., Miller, B. L., Schneider, L. S., Doody, R. S., Lees, A., Golbe, L. I., Williams, D. R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70088-2 · Cited by 294 · see citing works

Tau-based therapies in neurodegeneration: opportunities and challenges

Li, C., & Götz, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.155 · Cited by 272 · see citing works

Multifaceted Roles of GSK‐3 in Cancer and Autophagy‐Related Diseases

Mancinelli, R., Carpino, G., Petrungaro, S., Mammola, C. L., Tomaipitinca, L., Filippini, A., Facchiano, A., Ziparo, E., & Giampietri, C. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/4629495 · Cited by 235 · see citing works

Four-repeat tauopathies

Rösler, T. W., Marvian, A. T., Brendel, M., Nykänen, N.-P., Höllerhage, M., Schwarz, S. C., Hopfner, F., Koeglsperger, T., Respondek, G., Schweyer, K., et al. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101644 · Cited by 219 · see citing works

Tau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies

Sinsky, J., Pichlerova, K., & Hanes, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179207 · Cited by 220 · see citing works

Role of Nrf2 in aging, Alzheimer’s and other neurodegenerative diseases

George, M., Tharakan, M., Culberson, J. W., Reddy, A. P., & Reddy, P. H. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101756 · Cited by 212 · see citing works

Promotion of natural tooth repair by small molecule GSK3 antagonists

Neves, V. C. M., Babb, R., Chandrasekaran, D., & Sharpe, P. T. (2017) · Scientific Reports · doi:10.1038/srep39654 · Cited by 204 · see citing works

Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging

Pandey, M. K., & DeGrado, T. R. (2016) · Theranostics · doi:10.7150/thno.14334 · Cited by 198 · see citing works

Tau-Centric targets and drugs in clinical development for the treatment of alzheimer's disease

Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Zecca, C., Barulli, M. R., Bellomo, A., Pilotto, A., et al. (2016) · BioMed Research International · doi:10.1155/2016/3245935 · Cited by 195 · see citing works

Frontotemporal lobar degeneration

Grossman, M., Seeley, W. W., Boxer, A. L., Hillis, A. E., Knopman, D. S., Ljubenov, P. A., Miller, B., Piguet, O., Rademakers, R., Whitwell, J. L., et al. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00447-0 · Cited by 178 · see citing works

Progressive Supranuclear Palsy

Golbe, L. I. (2014) · Seminars in Neurology · doi:10.1055/s-0034-1381736 · Cited by 178 · see citing works

Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome

Jabbari, E., Holland, N., Chelban, V., Jones, P. S., Lamb, R., Rawlinson, C. V., Guo, T., Costantini, A. A., Tan, M. M. X., Heslegrave, A., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.4347 · Cited by 176 · see citing works

Revisiting the grammar of Tau aggregation and pathology formation: how new insights from brain pathology are shaping how we study and target Tauopathies

Limorenko, G., & Lashuel, H. A. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00127b · Cited by 162 · see citing works

Nuclear GSK3β promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22

Zhou, A., Lin, K., Zhang, S., Chen, Y., Zhang, N., Xue, J., Wang, Z., Aldape, K., Xie, K., Woodgett, J. R., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3396 · Cited by 158 · see citing works

Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer’s disease? From preclinical studies to the clinical trials

Basheer, N., Smolek, T., Hassan, I., Liu, F., Iqbal, K., Zilka, N., & Novak, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02113-z · Cited by 159 · see citing works

An Overview on the Clinical Development of Tau-Based Therapeutics

Medina, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041160 · Cited by 156 · see citing works

GSK3: A Kinase Balancing Promotion and Resolution of Inflammation

Hoffmeister, L., Diekmann, M., Brand, K., & Huber, R. (2020) · Cells · doi:10.3390/cells9040820 · Cited by 148 · see citing works

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Höglinger, G. U., Litvan, I., Mendonça, N., Wang, D., Zheng, H., Rendenbach‐Mueller, B., Lon, H., Jin, Z., Fisseha, N., Budur, K. S., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30489-0 · Cited by 146 · see citing works

Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

Dam, T., Boxer, A. L., Golbe, L. I., Höglinger, G. U., Morris, H. R., Litvan, I., Lang, A. E., Corvol, J., Aiba, I., Grundman, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01455-x · Cited by 146 · see citing works

Therapy and clinical trials in frontotemporal dementia: past, present, and future

Tsai, R. M., & Boxer, A. L. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13640 · Cited by 145 · see citing works

Neurogenesis After Stroke: A Therapeutic Perspective

Rahman, A. A., Amruta, N., Pinteaux, E., & Bix, G. J. (2020) · Translational Stroke Research · doi:10.1007/s12975-020-00841-w · Cited by 142 · see citing works

Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s disease from a ferroptosis perspective

Derry, P. J., Hegde, M. L., Jackson, G. R., Kayed, R., Tour, J. M., Tsai, A.-L., & Kent, T. A. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101716 · Cited by 142 · see citing works

Lithium and Therapeutic Targeting of GSK-3

Snitow, M. E., Bhansali, R. S., & Klein, P. S. (2021) · Cells · doi:10.3390/cells10020255 · Cited by 145 · see citing works

The six brain‐specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes

Buchholz, S., & Zempel, H. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13784 · Cited by 145 · see citing works

Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies

Stamelou, M., Respondek, G., Giagkou, N., Whitwell, J. L., Kovács, G. G., & Höglinger, G. U. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00541-5 · Cited by 143 · see citing works

Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.

Boxer, A., Qureshi, I., Ahlijanian, M., Grundman, M., Golbe, L., Litvan, I., Honig, L. S., Tuite, P., McFarland, N. R., O'Suilleabhain, P., et al. (2019) · Lancet Neurology · doi:10.1016/s1474-4422(19)30139-5 · Cited by 115 · see citing works

Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues

Samudra, N. P., Lane‐Donovan, C., VandeVrede, L. A., & Boxer, A. L. (2023) · Journal of Clinical Investigation · doi:10.1172/jci168553 · Cited by 135 · see citing works

New Insights Into Drug Discovery Targeting Tau Protein

Soeda, Y., & Takashima, A. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.590896 · Cited by 133 · see citing works

Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward

Ruiz, S. M. A., & Eldar-Finkelman, H. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.792364 · Cited by 126 · see citing works

Development of disease-modifying drugs for frontotemporal dementia spectrum disorders

Panza, F., Lozupone, M., Seripa, D., Daniele, A., Watling, M., Giannelli, G., & Imbimbo, B. P. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0330-x · Cited by 122 · see citing works

Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions

Saraswati, A. P., Hussaini, S. M. A., Krishna, N. H., Babu, B. N., & Kamal, Ä. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.103 · Cited by 120 · see citing works

Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease

Dong, J., Cui, Y., Li, S., & Le, W. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151120123025 · Cited by 112 · see citing works

Therapeutic strategies for the treatment of tauopathies: Hopes and challenges

Khanna, M. R., Kovalevich, J., Lee, V. M. ‐., Trojanowski, J. Q., & Brunden, K. R. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.006 · Cited by 112 · see citing works

Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study

Jabbari, E., Koga, S., Valentino, R. R., Reynolds, R. H., Ferrari, R., Tan, M. M. X., Rowe, J. B., Dalgard, C. L., Scholz, S. W., Dickson, D. W., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30394-x · Cited by 111 · see citing works

Progressive supranuclear palsy: Advances in diagnosis and management

Coughlin, D. G., & Litvan, I. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.04.014 · Cited by 113 · see citing works

Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer’s Disease Multitarget Drug Discovery?: Miniperspective

De Simone, A., Tumiatti, V., Andrisano, V., & Milelli, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00931 · Cited by 110 · see citing works

Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy

Taylor, A., Rothstein, D. M., & Rudd, C. E. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0491 · Cited by 104 · see citing works

Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy

Zhou, J., Ahmad, F., Parikh, S. S., Hoffman, N. E., Rajan, S., Verma, V. K., Song, J., Yuan, A., Shanmughapriya, S., Guo, Y., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.308544 · Cited by 105 · see citing works

Tau-Based Therapeutics for Alzheimer’s Disease: Active and Passive Immunotherapy

Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Tortelli, R., Galizia, I., Prete, C., Daniele, A., et al. (2016) · Immunotherapy · doi:10.2217/imt-2016-0019 · Cited by 105 · see citing works

Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration

Rippin, I., & Eldar-Finkelman, H. (2021) · Cells · doi:10.3390/cells10020262 · Cited by 102 · see citing works

Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases

Xie, Z., Yang, X., Duan, Y., Han, J., & Liao, C. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01511 · Cited by 102 · see citing works

Treatment of Frontotemporal Dementia

Tsai, R. M., & Boxer, A. (2014) · Current Treatment Options in Neurology · doi:10.1007/s11940-014-0319-0 · Cited by 104 · see citing works

Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia

Wagner, F. F., Benajiba, L., Campbell, A. J., Weïwer, M., Sacher, J. R., Gale, J. P., Ross, L. S., Puissant, A., Alexe, G., Conway, A. S., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam8460 · Cited by 100 · see citing works

Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses

Şahin, İ., Eturi, A., Souza, A. O., Pamarthy, S., Tavora, F., Giles, F. J., & Carneiro, B. A. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1595283 · Cited by 96 · see citing works

Targeting tau: clinical trials and novel therapeutic approaches

VandeVrede, L., Boxer, A. L., & Polydoro, M. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.134919 · Cited by 90 · see citing works

Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options

Lamb, R., Rohrer, J. D., Lees, A. J., & Morris, H. R. (2016) · Current Treatment Options in Neurology · doi:10.1007/s11940-016-0422-5 · Cited by 95 · see citing works

Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality

Hu, Z., Chen, P.-H., Li, W., Douglas, T., Hines, J., Liu, Y., & Crews, C. M. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11706 · Cited by 98 · see citing works

The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy

Zhang, C., Xing, A., Tan, M., Tan, L., & Yu, J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9415-8 · Cited by 91 · see citing works

Clinical Approach to Progressive Supranuclear Palsy

Ling, H. (2016) · Journal of Movement Disorders · doi:10.14802/jmd.15060 · Cited by 93 · see citing works

Progressive Supranuclear Palsy: an Update

Armstrong, M. J. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0819-5 · Cited by 92 · see citing works

Progression of brain atrophy in PSP and CBS over 6 months and 1 year

Dutt, S., Binney, R. J., Heuer, H. W., Luong, P., Attygalle, S., Bhatt, P., Marx, G. A., Elofson, J., Tartaglia, M. C., Litvan, I., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003305 · Cited by 91 · see citing works

GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways

Demuro, S., Martino, R. M. C. D., Ortega, J. A., & Cavalli, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169098 · Cited by 85 · see citing works

Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials

Höglinger, G. U., Schöpe, J., Stamelou, M., Kassubek, J., del Ser, T., Boxer, A. L., Wagenpfeil, S., Huppertz, H., for the AL‐108‐231 Investigators, the Tauros MRI Investigators, et al. (2017) · Movement Disorders · doi:10.1002/mds.26973 · Cited by 84 · see citing works

Neuroinflammation predicts disease progression in progressive supranuclear palsy

Malpetti, M., Passamonti, L., Jones, P. S., Street, D., Rittman, T., Fryer, T. D., Hong, Y. T., Vàsquez Rodriguez, P., Bevan-Jones, W. R., Aigbirhio, F. I., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-325549 · Cited by 85 · see citing works

Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD

Hayes, L. R., & Kaláb, P. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01260-5 · Cited by 81 · see citing works

Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care

Bluett, B., Pantelyat, A. Y., Litvan, I., Ali, F., Apetauerova, D., Bega, D., Bloom, L., Bower, J. H., Boxer, A. L., Dale, M. L., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.694872 · Cited by 82 · see citing works

Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau

Josephs, K. A. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.04.016 · Cited by 80 · see citing works

Atypical parkinsonian syndromes: a general neurologist's perspective

Deutschländer, A., Ross, O. A., Dickson, D. W., & Wszołek, Z. K. (2017) · European Journal of Neurology · doi:10.1111/ene.13412 · Cited by 81 · see citing works

Molecular Mechanisms of Lithium Action: Switching the Light on Multiple Targets for Dementia Using Animal Models

Kerr, F., Bjedov, I., & Sofola-Adesakin, O. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00297 · Cited by 78 · see citing works

GSK-3β Contributes to Parkinsonian Dopaminergic Neuron Death: Evidence From Conditional Knockout Mice and Tideglusib

Li, J., Ma, S., Chen, J., Hu, K., Li, Y., Zhang, Z., Su, Z., Woodgett, J. R., Li, M., & Huang, Q. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00081 · Cited by 76 · see citing works

Diabetes and Alzheimer’s Disease: Might Mitochondrial Dysfunction Help Deciphering the Common Path?

Potenza, M. A., Sgarra, L., Desantis, V., Nacci, C., & Montagnani, M. (2021) · Antioxidants · doi:10.3390/antiox10081257 · Cited by 77 · see citing works

A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies

Imbimbo, B. P., Ippati, S., Watling, M., & Balducci, C. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12453 · Cited by 72 · see citing works

Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases

Palomo, V., Pérez, D. I., Roca, C., Anderson, C. J., Rodríguez‐Muela, N., Pérez, C., Morales-Garcia, J. A., Reyes, J. A., Campillo, N. E., Pérez‐Castillo, A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00395 · Cited by 74 · see citing works

Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer’s Disease

Shri, S. R., Manandhar, S., Nayak, Y., & Pai, K. S. R. (2023) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2023.071 · Cited by 71 · see citing works

GSK-3β and its Inhibitors in Alzheimer's Disease: A Recent Update

Sharma, S. K., Chauhan, N., Paliwal, S., Jain, S., Verma, K., & Paliwal, S. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220420094317 · Cited by 68 · see citing works

Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3β as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis

Martínez‐González, L., Gonzalo‐Consuegra, C., Gómez‐Almería, M., Porras, G., de Lago, E., Martín‐Requero, Á., & Martı́nez, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168975 · Cited by 68 · see citing works

Therapeutic Potential Effect of Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors in Parkinson Disease: Exploring an Overlooked Avenue

Turkistani, A. A., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Alexiou, A. T., Papadakis, M., Elfiky, M. M., Saad, ‏. M., & Batiha, G. E. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04003-z · Cited by 62 · see citing works

Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease

Benn, C., & Dawson, L. A. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00242 · Cited by 57 · see citing works

Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity

Huang, Y., Wu, Z., & Zhou, B. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2042-8 · Cited by 58 · see citing works

Tideglusib, a chemical inhibitor of GSK3β, attenuates hypoxic-ischemic brain injury in neonatal mice

Wang, H., Huang, S., Yan, K., Fang, X., Abussaud, A., Martinez, A., Sun, H.-S., & Feng, Z.-P. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.06.027 · Cited by 59 · see citing works

Open‐Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy

VandeVrede, L. A., Dale, M. L., Fields, S., Frank, M., Hare, E. B., Heuer, H. W., Keith, K., KOESTLER, M. E., Ljubenkov, P. A., McDermott, D., et al. (2020) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12940 · Cited by 56 · see citing works

Screening of tau protein kinase inhibitors in a tauopathy-relevant cell-based model of tau hyperphosphorylation and oligomerization

Yadikar, H., Torres, I., Aiello, G., Kurup, M., Yang, Z., Lin, F. Y., Kobeissy, F. H., Yost, R. A., & Wang, K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0224952 · Cited by 56 · see citing works

Glycogen Synthase Kinase 3β Involvement in Neuroinflammation and Neurodegenerative Diseases

Gianferrara, T., Cescon, E., Grieco, I., Spalluto, G., & Federico, S. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220216113517 · Cited by 58 · see citing works

The Progressive Supranuclear Palsy Clinical Deficits Scale

Piot, I., Schweyer, K., Respondek, G., Stamelou, M., DescribePSP study group, ProPSP study group, MDS‐endorsed PSP study group, Sckopke, P., Schenk, T., Goetz, C. G., et al. (2020) · Movement Disorders · doi:10.1002/mds.27964 · Cited by 55 · see citing works

Modeling neurodegenerative diseases with cerebral organoids and other three-dimensional culture systems: focus on Alzheimer’s disease

Venkataraman, L., Fair, S. R., McElroy, C. A., Hester, M. E., & Fu, H. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10068-9 · Cited by 54 · see citing works

Aberrant regulation of the GSK‐3β/NRF2 axis unveils a novel therapy for adrenoleukodystrophy

Ranea‐Robles, P., Launay, N., Ruíz, M., Calingasan, N. Y., Dumont, M., Naudí, A., Portero‐Otín, M., Pamplona, R., Ferrer, I., Beal, M. F., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708604 · Cited by 55 · see citing works

Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015)

Palomo, V., & Martı́nez, A. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1259412 · Cited by 54 · see citing works

Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy

Leclair‐Visonneau, L., Rouaud, T., Debilly, B., Durif, F., Houéto, J., Kreisler, A., Defebvre, L., Lamy, E., Volteau, C., Nguyen, J., et al. (2016) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2016.04.021 · Cited by 53 · see citing works

Four-Repeat Tauopathies: Current Management and Future Treatments

VandeVrede, L. A., Ljubenkov, P. A., Rojas, J. C., Welch, A. E., & Boxer, A. L. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00888-5 · Cited by 53 · see citing works

Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium

Seripa, D., Solfrizzi, V., Imbimbo, B. P., Daniele, A., Santamato, A., Lozupone, M., Zuliani, G., Greco, A., Logroscino, G., & Panza, F. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1140039 · Cited by 50 · see citing works

Managing Cognition in Progressive Supranuclear Palsy

Rittman, T., Coyle-Gilchrist, I. T. S., & Rowe, J. B. (2016) · Neurodegenerative Disease Management · doi:10.2217/nmt-2016-0027 · Cited by 50 · see citing works

MiR-9-5p inhibits mitochondrial damage and oxidative stress in AD cell models by targeting GSK-3β

Liu, J., Zuo, X., Han, J., Dai, Q., Xu, H., Liu, Y., & Cui, S. (2020) · Bioscience, Biotechnology, and Biochemistry · doi:10.1080/09168451.2020.1797469 · Cited by 47 · see citing works

Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials

Bang, J., Lobach, I. V., Lang, A. E., Grossman, M., Knopman, D. S., Miller, B. L., Schneider, L. S. S., Doody, R. S., Lees, A. J., Gold, M., et al. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.04.014 · Cited by 48 · see citing works

Novel treatments for autism spectrum disorder based on genomics and systems biology

Baribeau, D. A., & Anagnostou, E. A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107939 · Cited by 50 · see citing works

Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles

Kidwell, K., Roychoudhury, S., Wendelberger, B. A., Scott, J., Moroz, T., Yin, S., Majumder, M., Zhong, J., Huml, R. A., & Miller, V. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02342-5 · Cited by 48 · see citing works

Advances in Alzheimer's disease: A multifaceted review of potential therapies and diagnostic techniques for early detection

Sharma, M., Pal, P., & Gupta, S. K. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105761 · Cited by 48 · see citing works

Corticobasal degeneration

Saranza, G., Whitwell, J. L., Kovács, G. G., & Lang, A. E. (2019) · International review of neurobiology · doi:10.1016/bs.irn.2019.10.014 · Cited by 48 · see citing works

An effective treatment for Alzheimer's disease must consider both amyloid and tau

Lansdall, C. J. (2014) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzu002 · Cited by 45 · see citing works

Disentangling tau: One protein, many therapeutic approaches

Lane‐Donovan, C., & Boxer, A. L. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00321 · Cited by 44 · see citing works

The redox-sensitive GSK3β is a key regulator of glomerular podocyte injury in type 2 diabetic kidney disease

Chen, M., Fang, Y., Ge, Y., Qiu, S., Dworkin, L. D., & Gong, R. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103127 · Cited by 47 · see citing works

Regulation of the Nrf2 Pathway by Glycogen Synthase Kinase-3β in MPP+-Induced Cell Damage

Armağan, G., Sevgili, E., Gürkan, F. T., Köse, F. A., Bilgiç, T., Dağcı, T., & Saso, L. (2019) · Molecules · doi:10.3390/molecules24071377 · Cited by 45 · see citing works

Glycogen synthase kinase-3: A potential preventive target for prostate cancer management

Li, B., Thrasher, J. B., & Terranova, P. F. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.05.006 · Cited by 45 · see citing works

Atypical Parkinsonism

Stamelou, M., & Bhatia, K. P. (2014) · Neurologic Clinics · doi:10.1016/j.ncl.2014.09.012 · Cited by 43 · see citing works

O4‐12‐02: Tideglusib, a GSK‐3 inhibitor, reduces progression of brain atrophy in progressive supranuclear palsy

Höglinger, G. U., Huppertz, H., Wagenpfeil, S., de Andrés, M. V., León, T., & del Ser, T. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.08.028 · Cited by 3 · see citing works

Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial

Höglinger, G. U., Huppertz, H., Wagenpfeil, S., Andrés, M. V., Belloch, V., León, T., del Ser, T., & for the TAUROS MRI Investigators (2014) · Movement Disorders · doi:10.1002/mds.25815 · Cited by 161 · see citing works

Tideglusib, a GSK-3 inhibitor, reduces progression of brain atrophy in progressive supranuclear palsy

Höglinger, G. U., Huppertz, H., Wagenpfeil, S., Lipp, A., Kupsch, A. R., Berg, D. V., Mätzler, W., Ludolph, A. C., Kassubek, J., Oertel, W., et al. (2013) · Basal Ganglia · doi:10.1016/j.baga.2013.01.024 · Cited by 1 · see citing works

Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy

Leclair‐Visonneau, L., Rouaud, T., Debilly, B., Durif, F., Houéto, J., Kreisler, A., Defebvre, L., Lamy, E., Volteau, C., Nguyen, J., et al. (2016) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2016.04.021 · Cited by 53 · see citing works

Disease‐Modifying Treatments for Progressive Supranuclear Palsy

Stamelou, M., & Boxer, A. L. (2015) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12142 · Cited by 8 · see citing works